BOSTON--(BUSINESS WIRE)--Drug delivery company, pSivida Corp. (NASDAQ: PSDV)(ASX: PVA)(FF: PV3), together with its licensing and development partner, Alimera Sciences, have today reported the interim six-month safety and efficacy results from the first human pharmacokinetici (PK) study of Medidur™ FA, which will be marketed under the trade name Iluvien™, if approved by the U.S. Food and Drug Administration.
